An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologiesMUSUMECI, Domenica; ROVIELLO, Giovanni N; MONTESARCHIO, Daniela et al.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 3, pp 347-357, issn 0163-7258, 11 p.Article

Artemisinins: Pharmacological actions beyond anti-malarialHO, Wanxing Eugene; HONG YONG PEH; TZE KHEE CHAN et al.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 1, pp 126-139, issn 0163-7258, 14 p.Article

Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoasterMOUNTZIOS, Giannis; PENTHEROUDAKIS, George; CARMELIET, Peter et al.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 2, pp 117-124, issn 0163-7258, 8 p.Article

CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapyMcNEELY, S; BECKMANN, R; BENCE LIN, A. K et al.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 1, pp 1-10, issn 0163-7258, 10 p.Article

Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathwaysHUYNH, Karina; BERNARDO, Bianca C; MCMULLEN, Julie R et al.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 3, pp 375-415, issn 0163-7258, 41 p.Article

HER3, serious partner in crime. Therapeutic approaches and potential biomarkers for effect of HER3-targetingKOL, Arjan; VAN SCHELTINGA, Anton G. T. Terwisscha; TIMMER-BOSSCHA, Hetty et al.Pharmacology & therapeutics (Oxford). 2014, Vol 143, Num 1, pp 1-11, issn 0163-7258, 11 p.Article

How anchoring proteins shape painFISCHER, Michael J. M; McNAUGHTON, Peter A.Pharmacology & therapeutics (Oxford). 2014, Vol 143, Num 3, pp 316-322, issn 0163-7258, 7 p.Article

Imaging aspects of the tumor stroma with therapeutic implicationsNARUNSKY, Lian; OREN, Roni; BOCHNER, Filip et al.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 2, pp 192-208, issn 0163-7258, 17 p.Article

Microbiota abnormalities in inflammatory airway diseases — Potential for therapyGOLLWITZER, Eva S; MARSLAND, Benjamin J.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 1, pp 32-39, issn 0163-7258, 8 p.Article

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathwayPOLIVKA, Jiri; JANKU, Filip.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 2, pp 164-175, issn 0163-7258, 12 p.Article

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic reviewSTINGL, J. C; BARTELS, H; VIVIANI, R et al.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 1, pp 92-116, issn 0163-7258, 25 p.Article

Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatmentVARBO, Anette; BENN, Marianne; NORDESTGAARD, Børge G et al.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 3, pp 358-367, issn 0163-7258, 10 p.Article

Targeting mast cells in inflammatory diseasesREBER, Laurent L; FROSSARD, Nelly.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 3, pp 416-435, issn 0163-7258, 20 p.Article

Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary diseaseYEGANEH, Behzad; WIECHEC, Emilia; GHAVAMI, Saeid et al.Pharmacology & therapeutics (Oxford). 2014, Vol 143, Num 1, pp 87-110, issn 0163-7258, 24 p.Article

The cardioprotective effects of mineralocorticoid receptor antagonistsVAN DEN BERG, T. N. A; RONGEN, Gerard A; FRÖHLICH, Georg M et al.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 1, pp 72-87, issn 0163-7258, 16 p.Article

The role of FAK in tumor metabolism and therapyJIANLIANG ZHANG; HOCHWALD, Steven N.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 2, pp 154-163, issn 0163-7258, 10 p.Article

Unifying Family A GPCR Theories of ActivationTEHAN, Benjamin G; BORTOLATO, Andrea; BLANEY, Frank E et al.Pharmacology & therapeutics (Oxford). 2014, Vol 143, Num 1, pp 51-60, issn 0163-7258, 10 p.Article

Metabotropic glutamatergic receptors and their ligands in drug addictionPOMIERNY-CHAMIOŁO, Lucyna; RUP, Kinga; POMIERNY, Bartosz et al.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 3, pp 281-305, issn 0163-7258, 25 p.Article

Current status of local therapy in malignant gliomas ― A clinical review of three selected approachesJURATLI, Tareq A; SCHACKERT, Gabriele; KREX, Dietmar et al.Pharmacology & therapeutics (Oxford). 2013, Vol 139, Num 3, pp 341-358, issn 0163-7258, 18 p.Article

Dengue virus therapeutic intervention strategies based on viral, vector and host factors involved in disease pathogenesisHERRERO, Lara J; ZAKHARY, Andrew; TAYLOR, Adam et al.Pharmacology & therapeutics (Oxford). 2013, Vol 137, Num 2, pp 266-282, issn 0163-7258, 17 p.Article

Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicityFERRI, Nicola; SIEGL, Peter; CORSINI, Alberto et al.Pharmacology & therapeutics (Oxford). 2013, Vol 138, Num 3, pp 470-484, issn 0163-7258, 15 p.Article

Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?HARRISON, Ian F; DEXTER, David T.Pharmacology & therapeutics (Oxford). 2013, Vol 140, Num 1, pp 34-52, issn 0163-7258, 19 p.Article

Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progressionPIENAAR, Ilse S; CHINNERY, Patrick F.Pharmacology & therapeutics (Oxford). 2013, Vol 137, Num 1, pp 1-21, issn 0163-7258, 21 p.Article

Minor groove binders as anti-infective agentsBARRETT, Michael P; GEMMELL, Curtis G; SUCKLING, Colin J et al.Pharmacology & therapeutics (Oxford). 2013, Vol 139, Num 1, pp 12-23, issn 0163-7258, 12 p.Article

Multiplicity of effectors of the cardioprotective agent, diazoxideCOETZEE, William A.Pharmacology & therapeutics (Oxford). 2013, Vol 140, Num 2, pp 167-175, issn 0163-7258, 9 p.Article